AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Bill Tracker · California

AB2489

Controlled substances: research.

Status

Pending

2026 Session

IntroducedFeb 20, 2026 (done)
PassedNext step (current)
Signed— (upcoming)
Law in effect— (upcoming)

Sponsor: Josh Lowenthal (Bipartisan)
Type: Clinical Research
Substances: Psilocybin

Official text

Summary (from PoliPsy)

An act to amend Sections 11213 and 11392 of, and to add and repeal Article 1.5 (commencing with Section 11214) of Chapter 5 of Division 10 of, the Health and Safety Code, relating to controlled substances.

The full bill text and every version are kept by the legislature. We link to it rather than copy it so readers always see the current version.

Read the full bill text

Source: leginfo.legislature.ca.gov

Legislative history

May 14, 2026
In committee: Held under submission.
April 29, 2026
Referred
April 13, 2026
Referred
April 8, 2026
Committee Report
March 9, 2026
Referred
February 20, 2026
Introduced

Loading bill…